Interview 21 Jun 2017 Video: Can Synbio Cure Malaria? – Fireside Chat with Oxitec’s CEO Hadyn Parry In our fireside chat with Hadyn Parry, Clara had the chance to hear all about Oxitec’s exciting technology that could save us from Dengue and Zika. Oxitec’s GM mosquitoes have the potential to halt epidemics of mosquito-borne diseases such as Zika or Dengue, which according to Hadyn are actually causing more problems every year. As Hadyn explained, “we’re […] June 21, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2017 British Biotech Tops up its Cancer Pipeline with New TCR Therapy Cell Medica just acquired Catapult Therapy TCR, set up by UK’s CGT Catapult, gaining the rights to its TCR therapy candidate to treat solid tumors. Cell Medica says it’s all set to leverage its Dominant T cell receptor (TCR) platform technology, which the company licensed from University College London (UCL) last year, to enhance existing T cell […] June 21, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2017 UK-based VC Launches Massive $300M Fund to Fill Gap for Late-Stage Biotech The UK-based VC Medicxi has raised a massive $300M (€268M) fund backed by Novartis and Google’s Verily to invest in late-stage drug development. After the former life science branch of famous Index Ventures went solo in 2016 and became Medicxi, the VC was able to raise a huge sum of €210M in its first round to support early-stage, single-asset […] June 15, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2017 MRC Technology, now LifeArc, Set to Invest £500M in UK’s Life Sciences LifeArc will draw funds from royalties of MSD’s successful checkpoint inhibitor Keytruda to invest in life sciences in both academic and business sectors. Born from the UK’s Medical Research Council, MRC Technology is a charity focused on supporting medical scientific research. Today, it becomes LifeArc and starts an ambitious new plan to invest up to […] June 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 12 Jun 2017 This Italian Academic-turned-CEO also Launched 7 Cancer Drugs at GSK Paolo Paoletti might have been forced to reconsider his career as a professor in medicine, but academia’s loss was biopharma’s gain! Before becoming CEO of one of London’s most exciting biotechs, GammaDelta Therapeutics, Paolo Paoletti had a long run through the corporate ranks of pharma. He was coaxed out of academic medicine to join Eli […] June 12, 2017 - 9 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 8 Jun 2017 Cambridge Antibody Technology: The History of the UK’s Best Biotech CAT was the first of Greg Winter’s three antibody-related companies and one of the UK’s biggest success stories in biotech. How did he pull it off? Sir Greg Winter is one of the biggest names in European biotech. As a Professor of Biochemistry at Cambridge University, he developed phage display technology that became the foundation […] June 8, 2017 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jun 2017 Imperial College Moves its Startup Incubator to a Bigger Facility in West London Last Friday, the Duke of York opened Imperial’s newest facilities in the White City campus, where the university is relocating its startup incubator. Imperial College’s startup incubator, previously located at Imperial’s South Kensington campus, just got a significant upgrade with brand new facilities that opened last week in Imperial College’s White City campus. The new space, aptly renamed the White City […] June 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 5 Jun 2017 What Lies Ahead in Biotech for the UK’s Top Academic Entrepreneur? Despite remaining firmly in academia, Greg Winter is a biotech legend. What’s ahead for the serial entrepreneur, and where does he see biotech going? Sir Greg Winter is one of the biggest names in European biotech. As a Professor of Biochemistry at Cambridge University, he developed phage display technology that became the foundation of his first […] June 5, 2017 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2017 Next-Gen Drug Conjugates Bank €46M in Series B with American Investors Bicycle Therapeutics has closed a massive fundraising round, raking in £40M (€46M) from American investors to launch clinical trials. Bicycle Therapeutics, the most recent company founded by the legendary academic-entrepreneur Greg Winter, is making a name for itself as a money magnet. Hot on the heels of a €1B deal with AstraZeneca last fall, the biotech […] June 1, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 30 May 2017 FDA Fast Tracks Muscular Dystrophy Drug backed by Woodford The FDA has handed out a Fast Track Designation to AMO Pharma for its key asset AMO-02 to treat congenital myotonic dystrophy. The British-American biotech hybrid AMO Pharma is advancing a small pipeline of drugs for rare genetic disorders. The biotech, which is backed by famous UK Investor Neil Woodford, is currently pushing its lead candidate […] May 30, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 26 May 2017 UPDATE: UK Cannabis Biotech ready for a Blockbuster in Rare Epilepsy UPDATE (26/05/2017): GW has released more positive results in The New England Journal of Medicine demonstrating that Epidiolex dramatically reduces convulsive seizures in children with Dravet syndrome. The results have primed the drug for its NDA submission to the FDA and led some to forecast blockbuster success. Original Publication 30/03/2016 GW Pharmaceuticals (UK) has announced positive results […] May 26, 2017 - 4 minutesmins - By Ekaterina Perets Share WhatsApp Twitter Linkedin Email
News and Trends 24 May 2017 UK biotech is catching up to the US, but will it run out of gas? The UK is far ahead of its European biotech rivals according to a new report, but will it fulfill its promise of becoming a global hub? According to analysis by the BioIndustry Association, the UK is catching up to global biotech leaders San Francisco and Boston, both in finance and R&D. British biotechs banked £1.13B last year, and […] May 24, 2017 - 5 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email